Brain tumors are one of the deadliest forms of cancer, therefore money for research is critical in finding new and effective forms of treatment. With the funds raised, we will:
Identify the most promising and innovative GBM research and/or clinical trials
Donate money to support GBM research to:
Identify effective Glioblastoma (GBM) brain tumor treatments and drugs
Increase survivability rates
Improve patient quality of life
Ultimately, find a cure for Glioblastoma (GBM) brain tumors
We will continue to designate funds for Glioblastoma research to the
Winship Cancer Institute at Emory, Harold C. Simmons Cancer Center of UT Southwestern in Texas, Robert H Lurie Comprehensive Caner Center and The National Brain Tumor Society-Defeat GBM Research Collaborative.
Harold C. Simmons has been designated by the National Cancer Institute (NCI) as a comprehensive center, an elite distinction held by only the top-tier cancer centers nationwide. The Simmons Cancer Center is the only cancer center in North Texas to attain this prestigious status, which is bestowed by the NCI in recognition of innovative research and excellence in patient care. Working with the Director of Development for Cancer Research at UTSW, we have decided to use the money from the Texas Ales for Ashley to support the work of Dr Maher. She is doing some great research using spectroscopy to determine if a certain gene is present in the tumor. With this information, new therapies and treatment options are available to the patient. We will make a three year commitment to fund this important research in North Texas. www.utswmed.org/medblog/dr-elizabeth-maher-through-lens-2hg/
Robert H. Lurie Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive center, an elite distinction held by only the top-tier cancer centers nationwide. The Lurie Cancer Center is the only institution in Chicago that possesses an NCI-supported Brain SPORE. Funds will support the work of Dr. Derek Wainwright, Ph.D. He is Principal Investigator of a brain cancer immunology and immunotherapy laboratory at Northwestern University, has previously conducted research that has been translated into multiple clinical trials for glioblastoma patients, and is currently expanding his research objectives into understanding how the molecular mechanisms of high distress levels, advanced aging, and immunosuppressive IDO1, suppress immunotherapeutic efficacy in patients diagnosed with malignant glioma. With this new information, innovative and exciting therapeutic treatment options are rapidly becoming available to improve the survival of patient with brain cancer.
The Defeat GBM Research Collaborative is a groundbreaking, research-based initiative that takes advantage of the convergence of exciting scientific advancements, an innovative business model, and support from biopharmaceutical companies to drive research forward with the aim of doubling the five-year survival rate of GBM patients. Building from the pioneering data discovered through The Cancer Genome Atlas (TCGA) and the growing commitment to true collaboration across disciplines and institutions, a new era of possibilities has been entered. http://defeatgbm.org/
Winship is one of 69 National Cancer Institute (NCI) designated cancer research centers in the United States. For 80 years, Winship has coordinated and directed cancer research, education and care throughout Emory University and its health care system, Emory Healthcare. Winship is ranked first in Georgia for cancer care and is top-ranked nationally by U.S. News & World Report.